Abstracts tagged "pain"

Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: L15 • ACR Convergence 2024
LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial
Philip Conaghan¹, Ali Guermazi², Nathaniel Katz³, Asger Bihlet⁴, Dror Rom⁵, Michael Perkins⁶, Bernadette Hughes⁶, Claire Herholdt⁶, Iwona Bombelka⁶ and Simon Westbrook⁶, ¹University of Leeds, Leeds, United Kingdom, ²Boston University, West Roxbury, MA, ³Rin Sof Innovation, Ltd, Boston, MA, ⁴NBCD A/S, Soeborg, Denmark, ⁵Prosoft Clinical, Chesterbrook, ⁶Levicept Ltd, Ramsgate, United Kingdom
Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…
Abstract Number: 0162 • ACR Convergence 2024
Statewide Burden of Low Back Pain in the United States and Its Trend from 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2022
Eva Kalra¹, Rafael Sanchez-Dopazo,², Lovekumar Vala³, Vani Sojitra⁴, Riya Dhadhal⁵, Praveena Suppala⁶, Mohammed A. S. Aramin⁷, Krishna Sajeev⁸ and Hardik Desai⁹, ¹Trident Medical Cente, Charleston, SC, ²Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ³Department of Internal Medicine, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India, 365601, Amreli, Gujarat, India, ⁴Pandit Deendayal Upadhyay Medical College, Rajkot,, Rajkot, Gujarat, India, ⁵SMIMER Hospital & Medical College, Surat, Gujarat, India, ⁶SVS Medical College, Yenugonda, Mahbubnagar, Telangana, India,, Telangana, Telangana, India, ⁷Alquds university,Jerusalem,Palestine, P144, Gaza, Palestinian Territories, ⁸Government medical college, Kannur, kerala , India, 670503, Kunnur, Kerala, India, ⁹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: Low back pain (LBP) ranks as the fourth leading cause of disability in the United States, significantly impacting the quality of life and work…
Abstract Number: 0790 • ACR Convergence 2024
CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study
Jonathan Samuels¹, Katherine Tse², Wei David², maryfe Coronel², Fernando Bomfim², Renata La Rocca Vieira³, Nicole Leung⁴, Svetlana Krasnokutsky Samuels⁵, Michael Toprover⁶ and Michael Pillinger⁷, ¹NYU Langone, Rye Brook, NY, ²NYU Langone Health, new york, NY, ³NYU., New York, NY, ⁴New York University Langone Medical Center, New York, NY, ⁵Summit Health, Rye Brook, NY, ⁶New York University Langone Health, New York, NY, ⁷New York University Grossman School of Medicine, New York,, NY
Background/Purpose: Knee osteoarthritis (OA) leads to progressive disability, but approved pharmacologic treatments target analgesia without affecting disease course. Colchicine is well-tolerated and inhibits inflammation thought…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 1228 • ACR Convergence 2024
Central Pain Mechanisms and Physical Function in Early Rheumatoid Arthritis
Burcu Aydemir¹, Lutfiyya Muhammad², Jing Song³, Dorothy Dunlop⁴, Kathleen Aren⁵, Mary Carns⁵, Wendy Marder⁶, Vivian Bykerk⁷, Kevin Deane⁸, Clifton Bingham⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Worthington, MN, ⁴Northwestern University, New Haven, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶University of Michigan, Ann Arbor, MI, ⁷Hospital For Special Surgery, New York, NY, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹Johns Hopkins University, Baltimore, MD
Background/Purpose: Despite effective control of inflammation, patients with rheumatoid arthritis (RA) may experience lingering pain and losses in physical function. Pain can occur because central…
Abstract Number: 1934 • ACR Convergence 2024
Knee Symptom Phenotyping Incorporating Pain and Function: A Multiple-Trajectory Modeling-Based Study Using Data from the Osteoarthritis Initiative (OAI)
Yong Ge¹, Thang Doung², Shen Liu³, Xiaoxiao Sun⁴, Tuhina Neogi⁵, Amanda Nelson⁶, Jeffery Duryea⁷ and Kent Kwoh⁸, ¹Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ²Department of Computer Science, University of Arizona College of Science, Tucson, AZ, ³Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁴Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸University of Arizona, Tucson, AZ
Background/Purpose: Knee pain is the most common presenting symptom of knee OA, and functional limitations are a common sequelae. Understanding the various patterns of pain…
Abstract Number: 2217 • ACR Convergence 2024
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Gilad Halpert¹, Eri Govrin², Boris Gilburd³, Shlomo Segev³, Omer Gendelman⁴, Abdulla Watad⁵, Yehuda Shoenfeld⁶, David Meiri⁷ and Howard Amital⁸, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Sdot Micha, Israel, ³Sheba Medical Center, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶sheba medical center , Israel, Ramat Gan, Israel, ⁷Technion-Israel Institute of Technology, Haifa, Israel, ⁸Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
Abstract Number: 0175 • ACR Convergence 2024
Do Knee Strength and Pain Relate to Developing Stair Climbing Difficulty for Knee Osteoarthritis?
Jason Jakiela¹, Yvonne Golightly², Sydney Liles³, Judy Foxworth⁴ and Daniel White⁵, ¹Winston-Salem State University, Winston-Salem, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of Delaware, Elkton, MD, ⁴Winston-Salem State University, Elon, NC, ⁵University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and stair climbing difficulty is often the first-reported limitation. Previous work…
Abstract Number: 0791 • ACR Convergence 2024
Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset
Caroline Walton¹, Forrest Hurley², Liubov Arbeeva³, Stephen Messier⁴, Shannon Mihalko⁴, Jeffrey Katz⁵, Richard Loeser⁶, David Hunter⁷, Leigh Callahan⁸ and Amanda Nelson², ¹UNC School of Medicine, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, Carrboro, NC, ⁴Wake Forest University, Winston Salem, NC, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶University of North Carolina, Chapel Hill, NC, ⁷Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Precision medicine has previously identified subgroups of clinical trial participants with knee osteoarthritis (kOA) that benefit more from a specific intervention than others. We…
Abstract Number: 1203 • ACR Convergence 2024
My Shoulder Hurts, What Should I Do? A Systematic Review and Bayesian Network Meta-analysis of Different Injectables in Glenohumeral Osteoarthritis
Mohamed Abdelsalam¹, Mona Sajed², Aya Alsaeed³, Heba Abdelrahman⁴, roaa Rafat⁵, Mohamed Tarek⁶ and Asmaa al-Najjar⁷, ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt, ³Faculty of medicine - Mansoura university, Mansoura, Ad Daqahliyah, Egypt, ⁴Faculty of medicine - Mansora university, Mansoura, Ad Daqahliyah, Egypt, ⁵Faculty of medicine, Ahfad University for Women, Khartoum, Sudan, Cairo, Egypt, ⁶Faculty of medicine - Al-Azhar university Cairo branch, Cairo, Egypt, ⁷Faculty of medicine - Al-Azhar university in Gaza, Gaza, Palestinian Territories
Background/Purpose: Glenohumeral Osteoarthritis (GH OA) significantly impacts joint function and quality of life. Various intraarticular injectable treatments, including hyaluronic acid (HA), corticosteroids (GCs), platelet-rich plasma…
Abstract Number: 1230 • ACR Convergence 2024
Mediating Role of Pain Catastrophizing in Racial Disparities in Knee Osteoarthritis Pain Among Non-Hispanic White and Asian Americans: A Pilot Study
Chiyoung Lee¹, Kent Kwoh² and Hyochol Ahn¹, ¹University of Arizona College of Nursing, Tucson, AZ, ²University of Arizona, Tucson, AZ
Background/Purpose: The prevalence of symptomatic knee osteoarthritis (OA) is projected to increase among racially and ethnically marginalized groups. Although recent studies have begun to delineate…
Abstract Number: 2087 • ACR Convergence 2024
Association of MRI-Defined Structure Features at Baseline with Knee Pain and Function Trajectories: Data from the Osteoarthritis Initiative (OAI)
Shen Liu¹, Thang Doung², Yong Ge³, Xiaoxiao Sun⁴, Yvonne Golightly⁵, Amanda Nelson⁶, Tuhina Neogi⁷, Jeffery Duryea⁸ and Kent Kwoh⁹, and Osteoarthritis Initiative (OAI) and Pivotal Osteoarthritis MRI Analyses (POMA) investigators, ¹Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ²Department of Computer Science, University of Arizona College of Science, Tucson, AZ, ³Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ⁴Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹University of Arizona, Tucson, AZ
Background/Purpose: Characterizing knee symptom (i.e., pain and function) trajectories and understanding differences among symptom trajectories have the potential to promote the development of customized treatment…
Abstract Number: 2246 • ACR Convergence 2024
Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial
Veena Ranganath¹, Holly Wilhalme², Nicolette Morris³, Jenny Brook², Mihaela Taylor¹, Howard Yang¹, Tanaz Kermani⁴, Thanda Aung², Brian Skaggs¹, David Elashoff⁵ and ziva Cooper⁶, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA, ⁴University of California Los Angeles, Santa Monica, CA, ⁵UCLA Department of Medicine Statistics Core, Los Angeles, ⁶UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles
Background/Purpose: There is no cure for rheumatoid arthritis (RA) and remission rates vary greatly 10-60%; thus, there is an unmet need for safe adjunctive therapeutic…
Abstract Number: 0281 • ACR Convergence 2024
Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Julien GRASSOT¹, Farah MARZOUKI², Roxane HERVE³, Magali BECKLER⁴, Luca SEMERANO⁵, Natacha BESSIS⁶, Elodie RIVIERE⁷, Charles SANSON², Gauthier POULIQUEN², Philippe POULETTY⁸ and Marie-Christophe BOISSIER⁹, ¹PK MED, LYON, Rhone-Alpes, France, ²PK MED, LYON, France, ³INSERM U1125, Bobigny, France, ⁴INSERM 1125, Bobigny, France, ⁵Avicenne Teaching Hospital APHP, Bobigny, France, ⁶INSERM, Université Sorbonne Paris Nord, PARIS, France, ⁷INSERM, Université Sorbonne Paris Nord, APHP, PARIS, France, ⁸PK MED, PARIS, France, ⁹University Sorbonne Paris Nord, Bobigny, France
Background/Purpose: Gout is a common disease with a prevalence and incidence on the rise worldwide. However, approved treatments to treat acute gout flares have slow…

1
2
3
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.